What we know and do not know about fingolimod

Outline and interpretation of results from the Japanese fingolimod core and extension studies

研究成果: ジャーナルへの寄稿評論記事

抄録

Multiple sclerosis (MS) is an idiopathic demyelinating disease of the central nervous system (CNS). Autoreactive T cells that recognize undetermined CNS antigens are assumed to mediate the disease. Fingolimod or FTY720, a sphingosine 1-phosphate receptor (S1PR) modulator, downmodulates S1PR on lymphocytes causing retention of circulating lymphocytes in the lymph nodes, including the CNS antigen-autoreactive lymphocytes that invade the CNS. Fingolimod has recently been approved in several countries as a once-daily, oral, disease-modifying drug for relapsing-remitting MS. Recently, the Japanese fingolimod core and extension studies showed the efficacy of fingolimod in terms of brain magnetic resonance imaging criteria and clinical activities in Japanese patients with relapsing MS without longitudinally extensive spinal cord lesions (LESCL). These results were consistent with the effects of fingolimod in Caucasian MS patients. No new safety issues were observed except for severe exacerbations that occurred in four anti-aquaporin-4 antibody-positive cases in whom LESCL were absent at the time of the entry. Thus, fingolimod is regarded as efficacious and safe for Asian MS patients, although Asian neuromyelitis optica cases in the early course of the disease should be excluded from fingolimod treatment.

元の言語英語
ページ(範囲)10-18
ページ数9
ジャーナルClinical and Experimental Neuroimmunology
5
発行部数1
DOI
出版物ステータス出版済み - 2014

Fingerprint

Multiple Sclerosis
Central Nervous System
Lysosphingolipid Receptors
Lymphocytes
Spinal Cord
Mouth Diseases
Aquaporin 4
Neuromyelitis Optica
Antigens
Relapsing-Remitting Multiple Sclerosis
Fingolimod Hydrochloride
Demyelinating Diseases
Lymph Nodes
Magnetic Resonance Imaging
T-Lymphocytes
Safety
Antibodies
Brain
Pharmaceutical Preparations
Therapeutics

All Science Journal Classification (ASJC) codes

  • Neuroscience (miscellaneous)
  • Immunology
  • Immunology and Microbiology (miscellaneous)
  • Clinical Neurology

これを引用

@article{0f31891735bb4a86a67dfc50cfb2d2ff,
title = "What we know and do not know about fingolimod: Outline and interpretation of results from the Japanese fingolimod core and extension studies",
abstract = "Multiple sclerosis (MS) is an idiopathic demyelinating disease of the central nervous system (CNS). Autoreactive T cells that recognize undetermined CNS antigens are assumed to mediate the disease. Fingolimod or FTY720, a sphingosine 1-phosphate receptor (S1PR) modulator, downmodulates S1PR on lymphocytes causing retention of circulating lymphocytes in the lymph nodes, including the CNS antigen-autoreactive lymphocytes that invade the CNS. Fingolimod has recently been approved in several countries as a once-daily, oral, disease-modifying drug for relapsing-remitting MS. Recently, the Japanese fingolimod core and extension studies showed the efficacy of fingolimod in terms of brain magnetic resonance imaging criteria and clinical activities in Japanese patients with relapsing MS without longitudinally extensive spinal cord lesions (LESCL). These results were consistent with the effects of fingolimod in Caucasian MS patients. No new safety issues were observed except for severe exacerbations that occurred in four anti-aquaporin-4 antibody-positive cases in whom LESCL were absent at the time of the entry. Thus, fingolimod is regarded as efficacious and safe for Asian MS patients, although Asian neuromyelitis optica cases in the early course of the disease should be excluded from fingolimod treatment.",
author = "Jun-Ichi Kira",
year = "2014",
doi = "10.1111/cen3.12098",
language = "English",
volume = "5",
pages = "10--18",
journal = "Clinical and Experimental Neuroimmunology",
issn = "1759-1961",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - What we know and do not know about fingolimod

T2 - Outline and interpretation of results from the Japanese fingolimod core and extension studies

AU - Kira, Jun-Ichi

PY - 2014

Y1 - 2014

N2 - Multiple sclerosis (MS) is an idiopathic demyelinating disease of the central nervous system (CNS). Autoreactive T cells that recognize undetermined CNS antigens are assumed to mediate the disease. Fingolimod or FTY720, a sphingosine 1-phosphate receptor (S1PR) modulator, downmodulates S1PR on lymphocytes causing retention of circulating lymphocytes in the lymph nodes, including the CNS antigen-autoreactive lymphocytes that invade the CNS. Fingolimod has recently been approved in several countries as a once-daily, oral, disease-modifying drug for relapsing-remitting MS. Recently, the Japanese fingolimod core and extension studies showed the efficacy of fingolimod in terms of brain magnetic resonance imaging criteria and clinical activities in Japanese patients with relapsing MS without longitudinally extensive spinal cord lesions (LESCL). These results were consistent with the effects of fingolimod in Caucasian MS patients. No new safety issues were observed except for severe exacerbations that occurred in four anti-aquaporin-4 antibody-positive cases in whom LESCL were absent at the time of the entry. Thus, fingolimod is regarded as efficacious and safe for Asian MS patients, although Asian neuromyelitis optica cases in the early course of the disease should be excluded from fingolimod treatment.

AB - Multiple sclerosis (MS) is an idiopathic demyelinating disease of the central nervous system (CNS). Autoreactive T cells that recognize undetermined CNS antigens are assumed to mediate the disease. Fingolimod or FTY720, a sphingosine 1-phosphate receptor (S1PR) modulator, downmodulates S1PR on lymphocytes causing retention of circulating lymphocytes in the lymph nodes, including the CNS antigen-autoreactive lymphocytes that invade the CNS. Fingolimod has recently been approved in several countries as a once-daily, oral, disease-modifying drug for relapsing-remitting MS. Recently, the Japanese fingolimod core and extension studies showed the efficacy of fingolimod in terms of brain magnetic resonance imaging criteria and clinical activities in Japanese patients with relapsing MS without longitudinally extensive spinal cord lesions (LESCL). These results were consistent with the effects of fingolimod in Caucasian MS patients. No new safety issues were observed except for severe exacerbations that occurred in four anti-aquaporin-4 antibody-positive cases in whom LESCL were absent at the time of the entry. Thus, fingolimod is regarded as efficacious and safe for Asian MS patients, although Asian neuromyelitis optica cases in the early course of the disease should be excluded from fingolimod treatment.

UR - http://www.scopus.com/inward/record.url?scp=84895451071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895451071&partnerID=8YFLogxK

U2 - 10.1111/cen3.12098

DO - 10.1111/cen3.12098

M3 - Review article

VL - 5

SP - 10

EP - 18

JO - Clinical and Experimental Neuroimmunology

JF - Clinical and Experimental Neuroimmunology

SN - 1759-1961

IS - 1

ER -